Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.
See you next year in Boston
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- Lexicon raises $130M in follow-on and notesLexicon Pharmaceuticals Inc. (NASDAQ:LXRX) raised $80 million through the sale of senior convertible notes and $50 million in a follow-on through the sale of 49.8 million shares at $1. JP Morgan; Goldman Sachs; Needham; and Stifel, Nicolaus are underwriters.
The notes bear 5.25% interest, mature in 2021 and initially convert at $1.21.
Lexicon expects top-line data in 3Q15 from a Phase III study of lead compound telotristat etiprate to treat carcinoid syndrome, which is associated with carcinoid tumors. The tryptophan hydroxylase inhibitor has Orphan Drug and Fast Track designations in the U.S. for this indication and Orphan Drug designation in the EU for carcinoid tumors.
Lexicon fell $0.06 to $0.95 on Friday.
Industry News from PharmAsia
- Japan Listing Sets Stage For Edoxaban, Vaniprevir LaunchesJapan has granted reimbursement prices to a batch of new drugs, including a new therapy for hepatitis C, a novel anticoagulant and a new insomnia treatment.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/J7Uoh0zPF0Y" height="1" width="1" />
Upcoming Supporter Events
Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel